1. Introduction {#sec1}
===============

Hearing impairment is a common sensorineural disease, affecting about one in 500--1000 children, and more than 50% congenital hearing loss is attributable to genetic origins \[[@B1]\]. Approximately, 70% of the deafness without other symptoms is known as nonsyndromic hearing loss (NSHL). Hereditary deafness can be classified as autosomal dominant, autosomal recessive, mitochondrial, and X-linked. Autosomal recessive nonsyndromic hearing loss (ARNSHL) is the most frequent hereditary pattern \[[@B2], [@B3]\].

Since *GJB2* was identified as the responsible gene for hereditary hearing loss \[[@B4]\], over 80 genes and 2000 mutations have been identified causing NSHL till now (<http://deafnessvariationdatabase.org>). *MYO15A* gene was revealed to be the disease-causing gene of ARNSHL \[[@B5]\]. Since then, more and more studies on *MYO15A* gene have focused on the mutational analysis. Usually, pathogenic mutations of *MYO15A* gene can cause congenital severe to profound hearing loss in all frequencies \[[@B6], [@B7]\], whereas some patients are noted to have residual hearings at low frequencies \[[@B8]\].

*MYO15A* gene consisting of 66 exons encodes a protein myosin XVA with 3530 amino acid. Myosin XVA can be classified into two isoforms: class 1 and class 2 \[[@B9]\]. They both contain six same domains: motor, MyTH, IQ, FERM, SH3, and PDZ. In addition, the class 1 isoform also has an N-terminal domain \[[@B10]--[@B12]\]. Both two isoforms can be found in the human inner ear \[[@B9]\].

Myosin XVA, expressed at the tips of stereocilia in the cochlea hair cells, is essential for the function of mechanotransduction apparatus \[[@B13]\], which is proved by a myosin XVA-deficient mouse model study \[[@B14]\].

Here, we report a consanguineous Chinese family affected by profound sensorineural hearing loss. We used SNPscan assay and targeted capture sequencing to identify the gene responsible for the deafness in the family. The results identified three compound heterozygous mutations, c.3971C\>A (p.A1324D), c.4011insA (p.Q1337Qfs^∗^22), and c.9690+1G\>A, in the *MYO15A* gene, and the first two of them were novel. Our finding would be a great supplement for the *MYO15A* pathogenic mutations and would make the genetic counseling available for this family.

2. Materials and Methods {#sec2}
========================

2.1. Subjects {#sec2.1}
-------------

This work was carried out with the permission of Shandong University ethical committee (number 014). All participants involved in the project signed written informed consent. A Chinese family affected by ARNSHL was recruited. The living family members consisted of four patients (V:3, V:4, IV:4, and IV:5, [Figure 1(a)](#fig1){ref-type="fig"}) and eight healthy persons. All affected members showed a bilateral congenital hearing loss. 200 normal persons were collected. All audiometric tests and physical examinations were evaluated at Shandong Provincial Hospital.

2.2. Clinical Evaluations {#sec2.2}
-------------------------

Audiometric assessments consist of auditory brainstem response, pure tone audiometry, distortion product otoacoustic emission, tympanometry, and acoustic stapedial reflex. The classification of deafness was based on the pure tone average (PTA) \[[@B15]\]. Hearing level was sorted into normal hearing (\<25 dBHL), mild deafness (\>25 and \<40 dBHL), moderate deafness (\>40 and \<60 dBHL), severe deafness (\>61 and \<80 dBHL), and profound deafness (\>80 dBHL) \[[@B16]\].

2.3. DNA Samples {#sec2.3}
----------------

A DNA extraction kit (AXYGEN) was employed to extract genomic DNA of all family members and 200 controls. Agarose gel electrophoresis was performed for evaluating the quality and quantity of DNA samples according to the routine protocol,

excluding common deafness genes.

In order to exclude mutations of *GJB2*, *SLC26A4*, and *MtDNA12SrRNA* genes, a "SNPscan assay" was employed. This SNPscan assay from Genesky Biotechnologies Inc. (Shanghai, China) was designed to capture a total of 115 mutations of the three common deafness-causing genes \[[@B17], [@B18]\]. It was carried out according to the detailed protocol described previously \[[@B19]\].

2.4. Targeted Capture Sequencing of Deafness Genes {#sec2.4}
--------------------------------------------------

After excluding common mutations, the targeted deafness gene capture was conducted by BGI Inc. (Wuhan, China). All exons, splicing sites, and flanking intron sequences of 127 hearing loss-related genes (Supplement Material: [Table S1](#supplementary-material-1){ref-type="supplementary-material"}) were captured. The workflow was (1) the fragmentization of Genomic DNA into 200--300 base pairs, (2) the construction of the genomic library, (3) the capture of targeted DNA fragments by hybridization to the capture array, (4) sequencing on Illumina HiSeq2000 Analyzers, and (5) data collection and bioinformatics analysis. The SOAPsnp software and the GATK IndelGenotyper were used to identify SNPs and indels, respectively. The NCBI dbSNP, 1000 Genomes, and the in-house database were also involved to filter SNPs \[[@B20]\].

2.5. Direct Sanger Sequencing {#sec2.5}
-----------------------------

Using targeted capture sequencing, we identified three candidate mutations. In order to determine whether these variants were cosegregated with hearing loss in the family, the PCR and Sanger sequencing were employed. Therefore, the following primers were synthesized: 5′-GATTGCCTGGTACCTCTGGG-3′ and 5′-AGCCTCCTCATCTTCCTGGT-3′ for human *MYO15A* c.3971C\>A and c.4011insA mutations and 5′-TCAGAGGATTGTGCGCCTTT-3′ and 5′-ATGCTCAGTCTTCCTGGCAC-3′ for human *MYO15A* c.9690+1G\>A mutation (BGI Inc., China). The PCR and amplification were performed according to a previous protocol \[[@B15]\]. Sequence alignment of *MYO15A* was performed using the DNASTAR software.

2.6. Functional Prediction {#sec2.6}
--------------------------

Next, phylogenetic analysis of different sequence alignments was performed by BioEdit. The included sequences were NP_057323.3 (human), XP_001077498.1 (rat), XP_015149897.1 (chicken), XP_009430930.1 (chimpanzee), XP_014974242.1 (monkey), XP_015323568.1 (cattle), and XP_015293218.1 (macaque).

2.7. Structure Modeling {#sec2.7}
-----------------------

Lastly, three-dimensional (3D) structure of the mutant and wild-type motor domain of *MYO15A* (NP_057323.3) was constructed by I-TASSER. These 3D models were visualized by Swiss-Pdb Viewer 4.01.

3. Result {#sec3}
=========

3.1. Subjects and Clinical Findings {#sec3.1}
-----------------------------------

Four affected patients (V-3, V-4, IV-4, and IV-5) and eight unaffected members (V-1, V-2, IV-2, IV-3, III-1, III-2, III-3, and III-4) in the consanguineous Chinese family with ARNSHL participated in this study ([Figure 1(a)](#fig1){ref-type="fig"}). The proband was 17 years old and suffered from congenital deafness. As shown in [Figure 1(b)](#fig1){ref-type="fig"}, all patients were affected with bilateral profound deafness with a flat audiogram revealed by PTA.

Clinical evaluations and otoscopy tests showed no abnormalities. Type A tympanograms were obtained from acoustic immittance tests, and there was no inner ear anomaly in patients revealed by MRI. ABR test revealed that the hearing loss of patients were all above 90 dBHL, and DPOAE were absent bilaterally from all patients. The clinical features of this family were summarized in [Table 1](#tab1){ref-type="table"}.

3.2. Targeted Deafness Gene Capture Sequencing {#sec3.2}
----------------------------------------------

All 127 hearing loss-related genes were sequenced in V-3, V-4, and IV-2 family members. Three mutations, c.3971C\>A (p.A1324D), c.4011insA (p.Q1337Qfs^∗^22), and c.9690+1G\>A, were detected in *MYO15A* gene (NM_016239), which were cosegregated with the disease, suggesting that these mutations may be the etiology of deafness in this ARNSHL family.

3.3. Confirmation of the Three Variants {#sec3.3}
---------------------------------------

The three *MYO15A* variants were confirmed by direct sequencing in all participating persons. The homozygous *MYO15A* mutation c.9690+1G\>A was detected in the affected patient IV-4. The compound heterozygous *MYO15A* variants c.3971C\>A and c.4011insA were detected in the affected patient IV-5. The compound heterozygous c.3971C\>A & c.9690+1G\>A and c.4011insA & c.9690+1G\>A were identified in the affected siblings, respectively (V-3, V-4) ([Figure 2(a)](#fig2){ref-type="fig"}). The other unaffected family members either carried only one heterozygous mutation or had a wild-type genotype ([Table 2](#tab2){ref-type="table"}). However, these variants were absent in two hundred ethnically matched control persons. To our knowledge, c.3971C\>A and c.4011insA variants were all considered as the first report and that three mutations identified in one family was quite rare.

The mutation c.3971C\>A of *MYO15A*, a missense mutation, leads to an alternation of an alanine with an aspartic at amino acid position 1324 (p.A1324D). The protein structure change caused by this mutation is predicted next. The mutation c.4011insA is an insertion mutation predicting to lead to a reading frame shift at position 1337 and a stop codon (p.Q1337Qfs^∗^22) and truncate the translation of mRNA resulting in lack of its complete length. The mutation c.9690+1G\>A was a splicing-site mutation resulting in a G to A transition at the donor splice site of intron 59. Thus, this mutation impaired the normal processing of mRNA formation.

The alignment of *MYO15A* from different species of human, rat, chicken, chimpanzee, monkey, cattle, and macaque was analyzed ([Figure 2(b)](#fig2){ref-type="fig"}). The result proved that p.A1324 and p.Q1337 were conservative among multiple species, which powerfully suggesting that these residues are important for the proper protein function.

3.4. Structural Modeling of p.A1324D in the Motor Domain of *MYO15A* {#sec3.4}
--------------------------------------------------------------------

A 3D simulative structure (PDB ID:1g8xA) of *MYO15A* motor domain was built, which contained the myosin XVA protein residues 1261--1887. The sequence identity between the template and target was 44% which was higher than the average 25%. We used Swiss-Pdb Viewer 4.1 software to analyze the mutated and wild structures of motor domain ([Figure 3](#fig3){ref-type="fig"}). The variant was speculated to affect the side chain because of the missense change. The prediction uncovered that this mutation caused damage to the protein function by means of the change of protein structure.

4. Discussion {#sec4}
=============

Changes in the *MYO15A* gene are known to be responsible for DFNB3 deafness. DFNB3 is the third pathogenic locus responsible for severe to profound ARNSHL. This report performed targeted capture sequence of 127 known deafness genes to describe genetic causes of a Chinese ARNSHL family. We identified three disease-causing *MYO15A* mutations finally. Multiple novel gene mutations revealed in one NSHL family are quite rare in the previous studies.

Our finding revealed that the variants p.A1324D and p.Q1337Qfs^∗^22 are located at myosin XVA motor domain. This region containing actin- and ATP-binding sites can produce the force that transports actin filaments in vitro \[[@B21]\]. The mutation p.A1324D is a missense change leading to an amino acid substitution, and p.Q1337Qfs^∗^22 results in a frameshift insertion and introduces a stop codon in the *MYO15A* open reading frame. A truncated protein is generated caused by the frameshift mutation. We estimate that the truncated protein is likely to be misexpressed or mislocated in the inner ear. Similarly to human DFNB3 hearing loss, a mouse model with homozygous variant in the myosin XVA motor domain exhibits profound hearing loss \[[@B22]\]. Many mutations were reported in this domain \[[@B8], [@B23]\] and were proposed probably to have deleterious effects on protein function.

Another mutation c.9690+1G\>A was first reported in 2015 \[[@B24]\]. It is a splicing-site mutation resulting in a G to A transition at the donor site and is predicted to locate between the junctional region of the posterior MyTH4 domain and the FERM domain in myosin XVA. Similarly to the myosin VIIA MyTH4-FERM domain, this region is important for the localization to the stereocilia tips \[[@B25], [@B26]\], which is essential for the normal function of the stereocilia tips. Therefore, we speculate that this mutation could weaken the MyTH4-FERM interface that leads to the disease.

To date, a number of mutations in *MYO15A* gene have been identified in hereditary hearing loss ([Figure 4](#fig4){ref-type="fig"}). Interestingly, the mutation spectrum of *MYO15A* varies among different ethnic populations. For example, a relatively low frequency of 0.89% (10/1120) was reported in a study of Japanese deafness cohort \[[@B27]\]. A mutational frequency of 3.3% was revealed in the Middle and South Asian areas \[[@B28]\]. In another genetic analysis study, 4% (5/125) was found in a Chinese ethnic population preexcluding common mutations \[[@B29]\]. Furthermore, a frequency of 5% was found in a Pakistani recessively inherited severe to profound hearing loss population \[[@B30]\]. And a higher frequency of 5.71% was reported in an Iranian population preexcluding GJB2 mutations \[[@B31]\]. Therefore, for every country, consummating its own *MYO15A* mutation spectrum is essential for the diagnosis and prevention of hearing loss.

In this family, we identified three novel mutations in *MYO15A* gene causing profound hearing loss. Exactly as literatures state, *MYO15A* variants have usually been regarded as the cause of congenital severe to profound deafness \[[@B6], [@B7]\]. However, recently, some families suffering from less severe hearing impairment were also diagnosed a genetic cause of *MYO15A* mutations. We find those mutations leading to less severe hearing loss are usually located in the N-terminal domain in reported literatures. We estimate that the defect caused by the mutations in the N-terminal domain other than the rest of the domains might be compensated by the existence of class 2 isoform which has no N-terminal domain. The N-terminal extension domain plays a less important role than the other parts of the gene in the protein function. Chang et al.\'s study in 2015 took the same ground \[[@B8]\].

In conclusion, three variants in *MYO15A* were identified using SNPscan assay and targeted capture sequencing: c.3971C\>A (p.A1324D), c.4011insA (p.Q1337Qfs^∗^22), and c.9690+1G\>A, and the first two of them were novel. All these mutations were cosegregated with the severe to profound deafness and were predicted to be pathogenic mutations. The present results also demonstrated that the combined application of SNPscan assay and targeted capture sequencing is a valuable and cost-saving molecular diagnostic strategy for ARNSHL. Our findings further extended the pathogenic variants of *MYO15A* gene in the ARNSHL group and would have a positive implication in genetic counseling for hearing loss families.
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###### 

Table S1: summary of the 127 targeted deafness genes.

###### 

Click here for additional data file.

![Clinical phenotype presentations of the pedigree. (a) Disease presentation of the family members and the pedigree map. All living members participated in the study, and V-3, V-4, and IV-2 were sequenced using capture gene sequencing. (b) Pure-tone audiograms of the family. Frequency in hertz (Hz) is plotted on the *x*-axis and the hearing level in decibels (dBHL) on the *y*-axis. The arrows in blue or red mean that the pure tones are not elicited at this point.](NP2018-5898025.001){#fig1}

![Sequence chromatograms and protein alignment. (a) The sequences of *MYO15A* at 3971, 4011, and 9690 + 1 of four family members. (b) The conservation of the p.A1324 and p.Q1337 residues (shown with black arrows) in healthy human, rat, chicken, chimpanzee, monkey, cattle, and macaque.](NP2018-5898025.002){#fig2}

![Structure modeling of wild-type and mutated MYO15A motor domain. (a) Green box shows the complete MYO15A motor domain. (b) The detailed structure of wild and mutated p.A1324 residue.](NP2018-5898025.003){#fig3}

![Reported mutations of *MYO15A* gene and their locations in the protein structure. The red characters refer to novel mutations identified in this study.](NP2018-5898025.004){#fig4}

###### 

Clinical features of the family.

  Subjects   Age     Age onset   Hearing loss   ABR     DPOAE   AR   MRI
  ---------- ------- ----------- -------------- ------- ------- ---- --------
  IV-2       57 yr   −           Normal         −       −       −    Normal
  IV-4       50 yr   0           Profound       95 dB   \+      \+   Normal
  IV-5       47 yr   0           Profound       95 dB   \+      \+   Normal
  V-3        19 yr   0           Profound       90 dB   \+      \+   Normal
  V-4        17 yr   0           Profound       90 dB   \+      \+   Normal

+: presence; −: absence.

###### 

Genotypes of all family members.

  Family member   Genotype       Zygosity       
  --------------- -------------- -------------- -----------------------
  III-1           c.9690+1G\>A                  Heterozygous
  III-2           c.9690+1G\>A                  Heterozygous
  III-3           c.4011insA                    Heterozygous
  III-4           c.3971C\>A                    Heterozygous
  IV-2            c.9690+1G\>A                  Heterozygous
  IV-3                                          Wild
  IV-4            c.9690+1G\>A                  Homozygous
  IV-5            c.3971C\>A     c.4011insA     Compound heterozygous
  V-1             c.9690+1G\>A                  Heterozygous
  V-2                                           Wild
  V-3             c.3971C\>A     c.9690+1G\>A   Compound heterozygous
  V-4             c.4011insA     c.9690+1G\>A   Compound heterozygous
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